Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD

  • Cingulate Inc CING is preparing to initiate a Phase 3 adult dose-optimization study later this year for its lead candidate, CTx-1301, to assess the onset and duration of efficacy and safety in adults with Attention Deficit / Hyperactivity Disorder (ADHD). 
  • The study is expected to commence in December 2022.
  • The company executed a Master Services Agreement with Societal CDMO Inc SCTL to manufacture all clinical, registration, and commercial batches of Cingulate's lead candidate CTx-1301, an investigational medication for ADHD.
  • In addition, the CTx-1301 Phase 3 fixed-dose pediatric and adolescent safety and efficacy study is now expected to commence in mid-2023 after the final two dosage strengths for this study are completed by Societal CDMO. 
  • Earlier this year, Cingulate expected to start the fixed-dose study in Q2 of 2022.
  • Assuming positive clinical results from Phase 3 trials and the food effect study with data expected in December 2022, the company plans to submit a marketing application to the FDA in 1H of 2024 under the Section 505(b)(2) pathway.
  • Price Action: CING shares closed 14.3% lower at $0.90 during after-hours trading on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!